AU2020254100B9 - Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors - Google Patents

Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors Download PDF

Info

Publication number
AU2020254100B9
AU2020254100B9 AU2020254100A AU2020254100A AU2020254100B9 AU 2020254100 B9 AU2020254100 B9 AU 2020254100B9 AU 2020254100 A AU2020254100 A AU 2020254100A AU 2020254100 A AU2020254100 A AU 2020254100A AU 2020254100 B9 AU2020254100 B9 AU 2020254100B9
Authority
AU
Australia
Prior art keywords
oleclumab
day
durvalumab
days
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020254100A
Other languages
English (en)
Other versions
AU2020254100A1 (en
AU2020254100B2 (en
Inventor
Zachary COOPER
Judson Englert
Charles FERTÉ
Anis Khan
Rakesh Kumar
Pablo Martinez Rodriguez
Nancy Kathryn MUELLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2020254100A1 publication Critical patent/AU2020254100A1/en
Publication of AU2020254100B2 publication Critical patent/AU2020254100B2/en
Application granted granted Critical
Publication of AU2020254100B9 publication Critical patent/AU2020254100B9/en
Priority to AU2025200063A priority Critical patent/AU2025200063A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2020254100A 2019-04-02 2020-04-01 Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors Active AU2020254100B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200063A AU2025200063A1 (en) 2019-04-02 2025-01-06 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828177P 2019-04-02 2019-04-02
US62/828,177 2019-04-02
PCT/IB2020/053110 WO2020202038A1 (en) 2019-04-02 2020-04-01 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200063A Division AU2025200063A1 (en) 2019-04-02 2025-01-06 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Publications (3)

Publication Number Publication Date
AU2020254100A1 AU2020254100A1 (en) 2021-11-18
AU2020254100B2 AU2020254100B2 (en) 2024-10-10
AU2020254100B9 true AU2020254100B9 (en) 2024-11-21

Family

ID=72663659

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020254100A Active AU2020254100B9 (en) 2019-04-02 2020-04-01 Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors
AU2025200063A Pending AU2025200063A1 (en) 2019-04-02 2025-01-06 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200063A Pending AU2025200063A1 (en) 2019-04-02 2025-01-06 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Country Status (13)

Country Link
US (1) US20200317803A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947447A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527334A (cg-RX-API-DMAC7.html)
KR (1) KR20210148253A (cg-RX-API-DMAC7.html)
CN (2) CN119857140A (cg-RX-API-DMAC7.html)
AU (2) AU2020254100B9 (cg-RX-API-DMAC7.html)
CA (1) CA3134671A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192587A1 (cg-RX-API-DMAC7.html)
IL (1) IL286504A (cg-RX-API-DMAC7.html)
MA (1) MA55558A (cg-RX-API-DMAC7.html)
SG (1) SG11202110694RA (cg-RX-API-DMAC7.html)
TW (1) TW202102545A (cg-RX-API-DMAC7.html)
WO (1) WO2020202038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301376A (en) * 2020-09-23 2023-05-01 Medimmune Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN120019073A (zh) * 2022-05-26 2025-05-16 天境生物科技(上海)有限公司 一种治疗实体瘤的方法
AU2023403103A1 (en) * 2022-12-01 2025-07-10 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
AU2017228470A1 (en) * 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
MX2019015885A (es) * 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Michael J. O. et al., Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). J. Clin. Oncol., vol 36, no 15_suppl, 2018 *
NCT03611556, "MEDI9447 (Oleclumab) Pancreatic Chemotherapy Combination Study.", MedImmune LLC, (2019-03-20), https://clinicaltrials.gov/study/NCT03611556?tab=history&a=8#references-card *
P Schmid, et al., Cancer Research, 2019; 79, no. 4_suppl, Abstract OT3-01-01 *

Also Published As

Publication number Publication date
CA3134671A1 (en) 2020-10-08
TW202102545A (zh) 2021-01-16
EA202192587A1 (ru) 2022-01-13
US20200317803A1 (en) 2020-10-08
WO2020202038A1 (en) 2020-10-08
JP2026031542A (ja) 2026-02-24
IL286504A (en) 2021-10-31
EP3947447A1 (en) 2022-02-09
AU2025200063A1 (en) 2025-01-30
EP3947447A4 (en) 2023-01-11
MA55558A (fr) 2022-02-09
SG11202110694RA (en) 2021-10-28
CN119857140A (zh) 2025-04-22
CN113993890A (zh) 2022-01-28
AU2020254100A1 (en) 2021-11-18
AU2020254100B2 (en) 2024-10-10
KR20210148253A (ko) 2021-12-07
JP2022527334A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
US11446377B2 (en) Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
AU2020254100B2 (en) Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors
US11866509B2 (en) Humanized antibodies against CEACAM1
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
JP2025060639A (ja) Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
JP2024511977A (ja) 抗ilt3抗体によるがんの治療方法
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
HK40118859A (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
EA047051B1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
AU2021330872A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
AU2024324720A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
HK40063551A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor
WO2020081783A2 (en) Anti-ox40, anti-pd-l1 and anti-ctla-4 antibodies for treating tumors

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)